1Q EARNINGS: Extraordinary factors help/hinder Takeda as Actos slumps
This article was originally published in Scrip
Takeda has raised its sales forecast for the current fiscal year ending next 31 March by JPY90.0bn to JPY1,680.0bn ($17.14bn) based on its first quarter performance, exchange rate outlook and the impact of the May acquisition of vaccines firm Inviragen.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.